BioLineRx (BLRX) Cost of Revenue (2013 - 2025)
BioLineRx (BLRX) posted Cost of Revenue of $40000.0 for Q4 2025, down 52.38% on a QoQ basis from $84000.0 in Q3 2025, and down 99.34% year-over-year from $6.1 million in Q4 2024.
BioLineRx (BLRX) has 13 years of Cost of Revenue data on file, last reported at $40000.0 in Q4 2025.
- In Q4 2025, Cost of Revenue fell 99.34% year-over-year to $40000.0; the TTM figure through Dec 2025 stood at $230000.0 (down 97.52% YoY), while the FY2025 annual figure was $230000.0, down 97.52% from the prior year.
- Cost of Revenue eased to $40000.0 in Q4 2025, from $84000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $8.1 million in Q3 2023 and bottomed at -$13.9 million in Q4 2023.
- A 5-year average of $1.0 million and a median of $729500.0 in 2022 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 1131.62% — and 2023, when it tumbled 515.43%.
- Year by year, Cost of Revenue stood at $272000.0 in 2021, then soared by 1131.62% to $3.4 million in 2022, then tumbled by 515.43% to -$13.9 million in 2023, then jumped by 143.75% to $6.1 million in 2024, then plunged by 99.34% to $40000.0 in 2025.
- The last three Cost of Revenue figures came in at $40000.0 (Q4 2025), $84000.0 (Q3 2025), and $72000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 207.52 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 40,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 40,000.00 |
| Dec 31, 2025 | 40,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Jun 30, 2025 | 72,000.00 |
| Jun 30, 2025 | 72,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 6.09 Mn |
| Dec 31, 2024 | 6.09 Mn |
| Sep 30, 2024 | 822,000.00 |
| Sep 30, 2024 | 822,000.00 |
| Jun 30, 2024 | 897,000.00 |
| Jun 30, 2024 | 897,000.00 |
| Mar 31, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | -13.92 Mn |
| Dec 31, 2023 | -13.92 Mn |
| Sep 30, 2023 | 8.13 Mn |
| Sep 30, 2023 | 8.13 Mn |
| Jun 30, 2023 | 5.60 Mn |
| Jun 30, 2023 | 5.60 Mn |
| Mar 31, 2023 | 3.87 Mn |
| Mar 31, 2023 | 3.87 Mn |
| Dec 31, 2022 | 3.35 Mn |
| Dec 31, 2022 | 3.35 Mn |
| Sep 30, 2022 | 1.32 Mn |
| Sep 30, 2022 | 1.32 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Mar 31, 2022 | 637,000.00 |
| Mar 31, 2022 | 637,000.00 |
| Dec 31, 2021 | 272,000.00 |
| Dec 31, 2021 | 272,000.00 |
| Sep 30, 2021 | 247,000.00 |
| Sep 30, 2021 | 247,000.00 |
| Jun 30, 2021 | 330,000.00 |
| Jun 30, 2021 | 330,000.00 |
| Mar 31, 2021 | 154,000.00 |
| Mar 31, 2021 | 154,000.00 |
| Dec 31, 2020 | 174,000.00 |
| Dec 31, 2020 | 174,000.00 |
| Sep 30, 2020 | 309,000.00 |
| Sep 30, 2020 | 309,000.00 |
| Jun 30, 2020 | 182,000.00 |
| Jun 30, 2020 | 182,000.00 |
| Mar 31, 2020 | 175,000.00 |
| Mar 31, 2020 | 175,000.00 |
| Dec 31, 2019 | 174,000.00 |
| Dec 31, 2019 | 174,000.00 |
| Sep 30, 2019 | 201,000.00 |
| Sep 30, 2019 | 201,000.00 |
| Jun 30, 2019 | 226,000.00 |
| Jun 30, 2019 | 226,000.00 |
| Mar 31, 2019 | 256,000.00 |
| Mar 31, 2019 | 256,000.00 |
| Dec 31, 2018 | 225,000.00 |
| Dec 31, 2018 | 225,000.00 |
| Sep 30, 2018 | 293,000.00 |
| Sep 30, 2018 | 293,000.00 |
| Jun 30, 2018 | 360,000.00 |
| Jun 30, 2018 | 360,000.00 |
| Mar 31, 2018 | 484,000.00 |
| Mar 31, 2018 | 484,000.00 |
| Dec 31, 2017 | 475,000.00 |
| Dec 31, 2017 | 475,000.00 |
| Sep 30, 2017 | 249,000.00 |
| Sep 30, 2017 | 249,000.00 |
| Jun 30, 2017 | 288,000.00 |
| Jun 30, 2017 | 288,000.00 |
| Mar 31, 2017 | 681,000.00 |
| Mar 31, 2017 | 681,000.00 |
| Dec 31, 2016 | 424,000.00 |
| Dec 31, 2016 | 424,000.00 |
| Sep 30, 2016 | 409,000.00 |
| Sep 30, 2016 | 409,000.00 |
| Jun 30, 2016 | 272,000.00 |
| Jun 30, 2016 | 272,000.00 |
| Mar 31, 2016 | 248,000.00 |
| Mar 31, 2016 | 248,000.00 |
| Dec 31, 2015 | 179,000.00 |
| Dec 31, 2015 | 179,000.00 |
| Sep 30, 2015 | 265,000.00 |
| Sep 30, 2015 | 265,000.00 |
| Jun 30, 2015 | 299,000.00 |
| Jun 30, 2015 | 299,000.00 |
| Mar 31, 2015 | 260,000.00 |
| Mar 31, 2015 | 260,000.00 |
| Dec 31, 2014 | 632,000.00 |
| Dec 31, 2014 | 632,000.00 |
| Sep 30, 2014 | 305,000.00 |
| Sep 30, 2014 | 305,000.00 |
| Jun 30, 2014 | 285,000.00 |
| Jun 30, 2014 | 285,000.00 |
| Mar 31, 2014 | 367,000.00 |
| Mar 31, 2014 | 367,000.00 |
| Dec 31, 2013 | 411,000.00 |
| Dec 31, 2013 | 411,000.00 |
| Sep 30, 2013 | 207,000.00 |
| Sep 30, 2013 | 207,000.00 |
| Jun 30, 2013 | 294,000.00 |
| Jun 30, 2013 | 294,000.00 |
| Mar 31, 2013 | 211,000.00 |
| Mar 31, 2013 | 211,000.00 |